Benzinga
Benzinga
Benzinga
vendredi, septembre 11

Adaptive Biotechnologies Corp

ADPTNASDAQ
Trade with Public
Trade with Public
$24.20
-0.03-0.12%
Dern. MÀJ: Sep 11, 9:07 AM
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatComparerOptionsRapport sur les stocks

Adaptive Biotechnologies Analyst Price Targets

Wall Street analyst price targets and consensus rating for Adaptive Biotechnologies (ADPT).

Price Target Range — 12 Quarters

Analyst Consensus — 7 Analysts

7Buy
Consensus RatingBuy# Analysts7Avg. Consensus PT$20Upside to Avg. PT-15.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →
DateFirmAnalystActionRating ChangePrice Target
Aug 4, 2026Piper SandlerDavid WestenbergPT RaiseOverweight$20→$28
Jul 30, 2026Morgan StanleyTejas SavantPT RaiseEqual-Weight$20→$22
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Piper Sandler Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $27.5

Piper Sandler analyst David Westenberg maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Overweight and raises the price target from $20 to $27.5.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $22

Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal-Weight and raises the price target from $20 to $22.
Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $28

TD Cowen analyst Dan Brennan maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $25 to $28.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $25

Guggenheim analyst Subbu Nambi maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $22 to $25.
Benzinga Newsdesk

PRO
BTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $25

BTIG analyst Mark Massaro maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $24 to $25.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $20

Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal-Weight and raises the price target from $18 to $20.
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Données de marché fournies par API Benzinga

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved